Introduction: To examine the comparative
INTRODUCTION
other factors contribute to OAG disease onset and progression. [2] [3] Over the past several decades, dozens of studies have linked abnormalities in ocular perfusion pressure (OPP) and blood flow to glaucomatous optic neuropathy. 4 Specifically, blood flow deficiencies of the retinal, choroidal, and retrobulbar circulations have been reported in patients with OAG. 4 In large population-based trials, reduced OPP has been linked to both the prevalence and incidence of glaucoma. [5] [6] [7] [8] Systemic and local vascular abnormalities have also been linked to OAG, including arterial hypertension, nocturnal hypotension, optic disc hemorrhage, migraine, and aging of the vasculature. 9 Mechanistically, reduced ocular perfusion may be secondary to IOP elevation or washout of the first study medication was followed by a second baseline examination and a crossover of study medications for an additional 1-month treatment period and final evaluation.
MATERIALS AND METHODS
Compliance of drug administration was based upon self-reporting.
All examinations were performed on one qualified study eye chosen at random by randomization chart. All measurements were performed in the same order, at the same time of day, and by the same examiner for each patient.
Measurements
Brachial artery systolic and diastolic blood pressure (SBP and DBP, respectively) and pulse were assessed after a 5-minute rest period using a calibrated automated sphygmomanometer at the beginning and end of each study visit.
IOP was assessed using Goldmann applanation tonometry. OPPs were calculated as two-thirds mean arterial pressure minus IOP.
CDI of the retrobulbar blood vessels was conducted using Philips High Definition Ima 
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Statistical Analysis
Statistical analyses were performed using the (Tables 1   and 2 , Figures 1 and 2) . A difference was noted in the sum of ranks of OA EDV between the four experimented conditions (Table 1) ; however, post-hoc analysis revealed no difference between the two drugs (Z score=1.19,
P=0.233).
When comparing treatments to individual baselines, both dorzolamide/timolol and brimonidine/timolol tended to increase PSV and EDV in the NPCA and TPCA, with a significant increase for dorzolamide/timolol in both blood vessels (Table 3) To the best of the authors' knowledge, there has been no prior published study that has reported on the ocular blood flow effects of 
